https://www.zacks.com/stock/news/2246078/compared-to-estimates-td-synnex-snx-q1-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2246078
Mar 26, 2024 - Although the revenue and EPS for TD SYNNEX (SNX) give a sense of how its business performed in the quarter ended February 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zc:1889130275208164764
0
https://seekingalpha.com/news/4083718-td-cowen-ups-stoke-to-buy-on-updated-data-for-epilepsy-drug?source=feed_sector_healthcare
Mar 26, 2024 - TD Cowen upgraded Stoke Therapeutics (STOK) to buy based on updated Phase 1/2 data for the company’s epilepsy drug candidate STK-001. Read more here.
0
sa:6773635004851759568
0
https://www.zacks.com/stock/news/2246889/td-bank-td-rolls-out-td-complete-checking-td-early-pay?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2246889
Mar 27, 2024 - TD Bank's (TD) TD Complete Checking and TD Early Pay offerings are set to offer customers convenience and help the company enhance its deposit balance.
zc:-5397587503412143624
0
https://seekingalpha.com/article/4681247-td-bank-good-time-to-buy-5-percent-yielding-blue-chip-deal?source=feed_all_articles
Mar 29, 2024 - TD Bank's financial position is vigorous enough to earn upper investment-grade credit ratings from the three major rating agencies. Read why I rate TD stock a buy.
0
sa:-7327915231277040651
0
https://seekingalpha.com/news/4089805-td-cowen-says-sickle-cell-therapies-may-get-higher-cms-payments?source=feed_sector_healthcare
Apr 15, 2024 - TD Cowen said recently approved gene therapies by Vertex (VRTX)/CRISPR (CRSP) and bluebird bio (BLUE) may get enhanced payments under proposed CMS guidelines. Read more here.
0
sa:1363788981963750155
0
https://www.zacks.com/stock/news/2260404/bsac-or-td-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2260404
Apr 23, 2024 - BSAC vs. TD: Which Stock Is the Better Value Option?
zc:-4256287534773767828
0
https://www.fool.com/investing/2024/04/27/2-incredibly-cheap-dividend-stocks-to-buy-now/?source=iedfolrf0000001
Apr 27, 2024 - These two dividend payers have historically high yields and attractive businesses, even though there are some headwinds to deal with.
0
fool:4622548458176325375
0
https://www.zacks.com/stock/news/2268282/compared-to-estimates-tds-tds-q1-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2268282
May 03, 2024 - The headline numbers for TDS (TDS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zc:8801071460809054784
0
https://www.zacks.com/stock/news/2230242/analysts-estimate-toronto-dominion-bank-td-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2230242
Feb 22, 2024 - Toronto-Dominion (TD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zc:-5740189925861518755
0
https://seekingalpha.com/news/4080047-td-cowen-cuts-immuneering-to-market-perform-cites-phase-1-data?source=feed_sector_healthcare
Mar 15, 2024 - TD Cowen has downgraded Immuneering (IMRX) to market perform, citing disappointing data from the company’s Phase 1 study for IMM-1-104 in treating solid tumors. Read more here.
0
sa:-7685492903346525306
0